EU regulator backs extending approval for remdesivir for another year
Reuters
Published May 21, 2021 13:32
Updated May 21, 2021 14:55
(Refiles to add dropped word "billion" in paragraph 5)
(Reuters) - The European Medicines Agency (EMA) on Friday recommended extending conditional marketing approval by a year for Gilead Sciences (NASDAQ:GILD)' COVID-19 treatment, remdesivir, the only drug so far that has been authorized for use in the region.
The regulator said its human medicines committee (CHMP) found that benefits of the drug outweighed risks, although the company was required to submit more data by the end of the year for the next scheduled renewal.
Remdesivir, sold under the brand name Veklury, was conditionally authorized in July last year for treating COVID-19 in adults and adolescents over 12 years with pneumonia requiring oxygen support.
In December, the regulator recommended changing some terms of the conditional approval after doubts over remdesivir's effectiveness were raised following a World Health Organization (WHO) panel's findings that there was no evidence the drug improved survival or reduced the need for ventilation.
Gilead last month posted 16% jump in first-quarter revenue to $6.4 billion, with remdesivir sales contributing $1.46 billion. It, however, said those sales would continue to be subject of significant volatility and uncertainty.
The conditional authorization allows approval of medicines that fulfill an unmet medical need with less complete data than normally expected, if the benefit of a medicine's immediate availability to patients outweighs any risks, and requires a re-assessment at least once a year.
(The story is refiled to add dropped word "billion" in paragraph 5)
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.